Vesugen vs Follistatin 344
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
VesugenAnabolic & IGF
Follistatin 344- Summary
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~24–36 hours
- Admin Route
- SubQ, Oral
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 100 mcg
- Frequency
- Daily for 10–30 days
- Once daily
- Key Benefits
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Inhibits myostatin — removes muscle growth ceiling
- Significant increases in muscle mass and strength
- Reduces fat mass
- Promotes bone density
- May stimulate hair follicle cycling
- Anti-fibrotic effects in muscle tissue
- Synergistic with IGF-1 and other anabolic peptides
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Muscle soreness (from rapid hypertrophy)
- Potential reproductive effects (activin inhibition)
- Unknown long-term safety profile
- Possible esophageal effects at high doses (animal data)
- Stacks With
- —
- —